Related Experiment Video

Updated: Jun 23, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

FGFR3-targeted mAb therapy for bladder cancer and multiple myeloma

Yaron Hadari1, Joseph Schlessinger

  • 1Kolltan Pharmaceuticals Inc., New Haven, Connecticut, USA.

The Journal of Clinical Investigation
|May 8, 2009
PubMed

Insights

Fibroblast growth factor receptor 3 (FGFR3) drives bladder cancer cell growth. An FGFR3-targeting antibody demonstrated antitumor effects in preclinical models, suggesting its potential for cancer therapy.

Area of Science:

  • Oncology
  • Molecular Biology

Background:

  • Gain-of-function mutations in Fibroblast Growth Factor Receptor 3 (FGFR3) are linked to skeletal dysplasias and cancers.
  • FGFR3 is implicated as a driver in various malignancies.

Discussion:

  • Qing et al. utilized shRNA probes to confirm FGFR3's role in bladder carcinoma cell proliferation.
  • An anti-FGFR3 monoclonal antibody (mAb) displayed significant antitumor activity.

Key Insights:

  • FGFR3 promotes bladder carcinoma cell proliferation.
  • Anti-FGFR3 mAb exhibits efficacy against human bladder cancer cells in vitro.
  • The mAb demonstrated antitumor effects in xenograft models of bladder cancer and multiple myeloma.

Outlook:

  • Targeted therapy using anti-FGFR3 mAbs warrants clinical consideration for cancer treatment.
  • Further research into FGFR3-targeted therapies may benefit other diseases.

More Related Videos

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...